Search Results - "Tom, Wynnis L"

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults by Paller, Amy S., MS, MD, Tom, Wynnis L., MD, Lebwohl, Mark G., MD, Blumenthal, Robin L., PhD, Boguniewicz, Mark, MD, Call, Robert S., MD, Eichenfield, Lawrence F., MD, Forsha, Douglass W., MD, Rees, William C., MD, Simpson, Eric L., MD, Spellman, Mary C., MD, Stein Gold, Linda F., MD, Zaenglein, Andrea L., MD, Hughes, Matilda H., CCRA, Zane, Lee T., MD, Hebert, Adelaide A., MD

“…Background Additional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks. Objective We sought to assess the…”
Get full text

Oral azathioprine for recalcitrant pediatric atopic dermatitis: Clinical response and thiopurine monitoring by Caufield, Maura, BA, Tom, Wynnis L., MD

“…Background Azathioprine is prescribed as a corticosteroid-sparing agent for many inflammatory conditions, including refractory atopic dermatitis (AD). There…”
Get full text

Pediatric psoriasis: Evolving perspectives by Eichenfield, Lawrence F., Paller, Amy S., Tom, Wynnis L., Sugarman, Jeffrey, Hebert, Adelaide A., Friedlander, Sheila Fallon, Siegfried, Elaine, Silverberg, Nanette, Cordoro, Kelly M.

“…Background/Objectives Childhood‐onset psoriasis is a common skin disorder that has recently received increasing attention, particularly because of its…”
Get full text

Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype by Haddock, Ellen S., AB, MBA, Calame, Antoanella, MD, Shimizu, Chisato, MD, Tremoulet, Adriana H., MD, Burns, Jane C., MD, Tom, Wynnis L., MD

“…Background A psoriasis-like eruption develops in a subset of patients with Kawasaki disease (KD). Objective We sought to systematically compare KD-associated…”
Get full text

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon by Chiu, Yvonne E., Drolet, Beth A., Blei, Francine, Carcao, Manuel, Fangusaro, Jason, Kelly, Michael E., Krol, Alfons, Lofgren, Sabra, Mancini, Anthony J., Metry, Denise W., Recht, Michael, Silverman, Robert A., Tom, Wynnis L., Pope, Elena

“…Propranolol is a non‐selective beta‐adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach–Merritt…”
Get full text

Pediatric “STUMP” lesions: Evaluation and management of difficult atypical Spitzoid lesions in children by Tom, Wynnis L., MD, Hsu, Jessica W., BS, Eichenfield, Lawrence F., MD, Friedlander, Sheila Fallon, MD

“…Spitz nevi represent a distinct type of melanocytic nevi more commonly seen in childhood. Although typically benign, a subset of Spitz lesions raise concern…”
Get full text

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis by Simpson, Eric L, Yosipovitch, Gil, Bushmakin, Andrew G, Cappelleri, Joseph C, Luger, Thomas, Ständer, Sonja, Tom, Wynnis L, Ports, William C, Zielinski, Michael A, Tallman, Anna M, Tan, Huaming, Gerber, Robert A

“…Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase…”
Get full text

Combined Intravenous Sildenafil and l-Arginine Administration in a Porcine Animal Model: Hemodynamic Safety Profile and Effects on Coronary Blood Flow by Brzezinski, Marek, Dincheva, Gabriela R., Alloo, Kelsey, Wong, Celeste, Feng, Chun-Miao, Tom, Wynnis L., Salahieh, Ali, Wallace, Arthur W.

“…Background Endothelial dysfunction in the nitric oxide-cyclic guanosine monophosphate pathway is a potential contributor to perioperative myocardial ischemia…”
Get full text

Atopic dermatitis: recent findings and insights by Tom, Wynnis L

Get more information

Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies by Eichenfield, Lawrence F, Tom, Wynnis L, Berger, Timothy G, Krol, Alfons, Paller, Amy S, Schwarzenberger, Kathryn, Bergman, James N, Chamlin, Sarah L, Cohen, David E, Cooper, Kevin D, Cordoro, Kelly M, Davis, Dawn M, Feldman, Steven R, Hanifin, Jon M, Margolis, David J, Silverman, Robert A, Simpson, Eric L, Williams, Hywel C, Elmets, Craig A, Block, Julie, Harrod, Christopher G, Smith Begolka, Wendy, Sidbury, Robert

“…Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses…”
Get full text

Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis by Eichenfield, Lawrence F, Tom, Wynnis L, Chamlin, Sarah L, Feldman, Steven R, Hanifin, Jon M, Simpson, Eric L, Berger, Timothy G, Bergman, James N, Cohen, David E, Cooper, Kevin D, Cordoro, Kelly M, Davis, Dawn M, Krol, Alfons, Margolis, David J, Paller, Amy S, Schwarzenberger, Kathryn, Silverman, Robert A, Williams, Hywel C, Elmets, Craig A, Block, Julie, Harrod, Christopher G, Smith Begolka, Wendy, Sidbury, Robert

“…Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses…”
Get full text

Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents by Sidbury, Robert, Davis, Dawn M, Cohen, David E, Cordoro, Kelly M, Berger, Timothy G, Bergman, James N, Chamlin, Sarah L, Cooper, Kevin D, Feldman, Steven R, Hanifin, Jon M, Krol, Alfons, Margolis, David J, Paller, Amy S, Schwarzenberger, Kathryn, Silverman, Robert A, Simpson, Eric L, Tom, Wynnis L, Williams, Hywel C, Elmets, Craig A, Block, Julie, Harrod, Christopher G, Begolka, Wendy Smith, Eichenfield, Lawrence F

“…Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important…”
Get full text

Guidelines of care for the management of atopic dermatitis by Sidbury, Robert, MD, Davis, Dawn M., MD, Cohen, David E., MD, Cordoro, Kelly M., MD, Berger, Timothy G., MD, Bergman, James N., MD, Chamlin, Sarah L., MD, MSCI, Cooper, Kevin D., MD, Feldman, Steven R., MD, PhD, Hanifin, Jon M., MD, Krol, Alfons, MD, Margolis, David J., MD, PhD, Paller, Amy S., MD, Schwarzenberger, Kathryn, MD, Silverman, Robert A., MD, Simpson, Eric L., MD, Tom, Wynnis L., MD, Williams, Hywel C., DSc, Elmets, Craig A., MD, Block, Julie, BA, Harrod, Christopher G., MS, Begolka, Wendy Smith, MBS, Eichenfield, Lawrence F., MD

“…Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important…”
Get full text

Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study by Tom, Wynnis L., Van Syoc, Merrie, Chanda, Sanjay, Zane, Lee T.

“…Background Phosphodiesterase‐4 (PDE4) is an emerging target in treating inflammatory skin diseases. Crisaborole topical ointment, 2% is a novel, boron‐based,…”
Get full text

Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches by Sidbury, Robert, Tom, Wynnis L, Bergman, James N, Cooper, Kevin D, Silverman, Robert A, Berger, Timothy G, Chamlin, Sarah L, Cohen, David E, Cordoro, Kelly M, Davis, Dawn M, Feldman, Steven R, Hanifin, Jon M, Krol, Alfons, Margolis, David J, Paller, Amy S, Schwarzenberger, Kathryn, Simpson, Eric L, Williams, Hywel C, Elmets, Craig A, Block, Julie, Harrod, Christopher G, Smith Begolka, Wendy, Eichenfield, Lawrence F

“…Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age groups. This evidence-based guideline addresses important clinical…”
Get full text

Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis by Stein Gold, Linda F, Tom, Wynnis L, Shi, Vivian, Sanders, Paul, Zang, Chuanbo, Vlahos, Bonnie, Cha, Amy

“…Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of patients with mild-to-moderate atopic dermatitis (AD). To assess…”
Get more information

Safety of Systemic Agents for the Treatment of Pediatric Psoriasis by Bronckers, Inge M G J, Seyger, Marieke M B, West, Dennis P, Lara-Corrales, Irene, Tollefson, Megha, Tom, Wynnis L, Hogeling, Marcia, Belazarian, Leah, Zachariae, Claus, Mahé, Emmanuel, Siegfried, Elaine, Philipp, Sandra, Szalai, Zsuzsanna, Vleugels, Ruth Ann, Holland, Kristen, Murphy, Ruth, Baselga, Eulalia, Cordoro, Kelly, Lambert, Jo, Alexopoulos, Alex, Mrowietz, Ulrich, Kievit, Wietske, Paller, Amy S

“…Use of systemic therapies for moderate to severe psoriasis in children is increasing, but comparative data on their use and toxicities are limited. To assess…”
Get more information

Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study by Paller, Amy S, Mercy, Katherine, Kwasny, Mary J, Choon, Siew Eng, Cordoro, Kelly M, Girolomoni, Giampiero, Menter, Alan, Tom, Wynnis L, Mahoney, Anne M, Oostveen, Annet M, Seyger, Marieke M B

“…To investigate the relationship of excess and central adiposity with pediatric psoriasis severity. Multicenter, cross-sectional study of 409 psoriatic…”
Get more information

Pediatric Psoriasis Comorbidity Screening Guidelines by Osier, Emily, Wang, Audrey S, Tollefson, Megha M, Cordoro, Kelly M, Daniels, Stephen R, Eichenfield, Andrew, Gelfand, Joel M, Gottlieb, Alice B, Kimball, Alexa B, Lebwohl, Mark, Mehta, Nehal N, Paller, Amy S, Schwimmer, Jeffrey B, Styne, Dennis M, Van Voorhees, Abby S, Tom, Wynnis L, Eichenfield, Lawrence F

“…Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type…”
Get more information

Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis by Leung, Donald Y.M., Paller, Amy S., Zaenglein, Andrea L., Tom, Wynnis L., Ong, Peck Y., Venturanza, May E., Kuligowski, Michael E., Li, Qian, Gong, Xiaohua, Lee, Mark S.

“…Therapies for children with atopic dermatitis (AD) have safety and tolerability concerns that may limit long-term use. Ruxolitinib cream, a Janus kinase (JAK)…”
Get full text